Cardiovascular

Latest News


Latest Videos


More News

CVD-REAL, the giant study of real-world evidence comparing sodium glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs to treat type 2 diabetes, found a 49% lower risk of all-cause death and a host of other benefits across 6 new, more diverse countries, the study’s lead author told a packed room Sunday at the 67th Scientific Session of the American College of Cardiology in Orlando, Florida.

Adults with obesity have an earlier onset of incident CVD, a greater proportion of life lived with CVD morbidity, and shorter overall survival compared with adults with normal BMI; and the proportion of adults with incident CVD events was significantly higher in adults who were classified as overweight or obese compared with adults with normal BMI, according to a study in JAMA Cardiology.

The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.